CA2284271C
(en)
|
1997-03-21 |
2012-05-08 |
Chugai Seiyaku Kabushiki Kaisha |
A preventive or therapeutic agent for sensitized t cell-mediated diseases comprising il-6 antagonist as an active ingredient
|
DK2261335T3
(en)
|
1998-11-27 |
2017-09-18 |
Ucb Pharma Sa |
Compositions and Methods for Increasing Bone Mineralization
|
BR0014486A
(pt)
*
|
1999-10-04 |
2002-09-17 |
Chiron Corp |
Composições farmacêuticas contendo polipeptìdeo lìquido estabilizado
|
PT1324776E
(pt)
*
|
2000-10-12 |
2009-12-23 |
Genentech Inc |
Formulações de proteína concentradas de viscosidade reduzida
|
US8703126B2
(en)
|
2000-10-12 |
2014-04-22 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
UA80091C2
(en)
|
2001-04-02 |
2007-08-27 |
Chugai Pharmaceutical Co Ltd |
Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
|
CA2975521A1
(en)
*
|
2001-05-30 |
2002-12-05 |
Genentech, Inc. |
Anti-ngf antibodies for the treatment of various disorders
|
GB0113179D0
(en)
*
|
2001-05-31 |
2001-07-25 |
Novartis Ag |
Organic compounds
|
AU2006202688B2
(en)
*
|
2001-05-31 |
2009-01-22 |
Genentech, Inc. |
Stable liquid formulations of antibodies
|
US20080026068A1
(en)
*
|
2001-08-16 |
2008-01-31 |
Baxter Healthcare S.A. |
Pulmonary delivery of spherical insulin microparticles
|
CN1292655C
(zh)
*
|
2001-11-08 |
2007-01-03 |
蛋白质设计实验室股份有限公司 |
IgG抗体稳定的液态药物制剂
|
IL165256A0
(en)
|
2002-05-24 |
2005-12-18 |
Schering Corp |
Neutralizing human anti-igfr antibody
|
US7425618B2
(en)
*
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
US20040002451A1
(en)
*
|
2002-06-20 |
2004-01-01 |
Bruce Kerwin |
Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
|
NZ537687A
(en)
*
|
2002-06-21 |
2008-04-30 |
Biogen Idec Inc |
Buffered formulations for concentrating antibodies and methods of use thereof
|
US20040033228A1
(en)
*
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
MY150740A
(en)
*
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
AU2003293543A1
(en)
*
|
2002-12-13 |
2004-07-09 |
Abgenix, Inc. |
System and method for stabilizing antibodies with histidine
|
EP1578394A4
(de)
*
|
2002-12-31 |
2011-02-23 |
Nektar Therapeutics |
Antikörperhaltige partikel und zusammensetzungen
|
WO2004062689A1
(en)
*
|
2003-01-08 |
2004-07-29 |
Chiron Corporation |
Stabilized aqueous compositions comprising tissue factor pathway inhibitor (tfpi) or tissue factor pathway inhibitor variant
|
US20040208870A1
(en)
*
|
2003-01-30 |
2004-10-21 |
Medimmune, Inc. |
Stabilized high concentration anti-integrin alphanubeta3 antibody formulations
|
ZA200507757B
(en)
*
|
2003-04-04 |
2007-01-31 |
Genentech Inc |
High concentration antibody and protein formulations
|
US20050158303A1
(en)
*
|
2003-04-04 |
2005-07-21 |
Genentech, Inc. |
Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
|
GB2401040A
(en)
*
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
EP1636270B1
(de)
|
2003-06-16 |
2016-07-20 |
UCB Pharma S.A. |
Spezifische antikörper für sclerostin und verfahren zur erhöhung der knochenmineralisierung
|
CA2530172A1
(en)
*
|
2003-06-27 |
2005-02-10 |
Abgenix, Inc. |
Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
|
DE10348550A1
(de)
*
|
2003-10-20 |
2005-06-16 |
Hexal Biotech Forschungsgmbh |
Stabile wässrige G-CSF-haltige Zusammensetzungen
|
US7585496B2
(en)
*
|
2003-11-04 |
2009-09-08 |
Lek Pharmaceuticals D.D. |
Stable pharmaceutical composition granulocyte-colony stimulating factor
|
US20050136055A1
(en)
*
|
2003-12-22 |
2005-06-23 |
Pfizer Inc |
CD40 antibody formulation and methods
|
EP1712240B1
(de)
*
|
2003-12-25 |
2015-09-09 |
Kyowa Hakko Kirin Co., Ltd. |
Stabile medizinische zubereitung auf wasserbasis mit antikörper
|
WO2005072772A1
(en)
*
|
2004-01-30 |
2005-08-11 |
Suomen Punainen Risti Veripalvelu |
Pharmaceutical compositions
|
US7884085B2
(en)
*
|
2004-05-12 |
2011-02-08 |
Baxter International Inc. |
Delivery of AS-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes
|
US8728525B2
(en)
*
|
2004-05-12 |
2014-05-20 |
Baxter International Inc. |
Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
|
US8333995B2
(en)
*
|
2004-05-12 |
2012-12-18 |
Baxter International, Inc. |
Protein microspheres having injectable properties at high concentrations
|
EP2072040B1
(de)
*
|
2004-05-12 |
2013-05-01 |
Baxter International Inc. |
Therapeutische Verwendung von Nukleinsäure-Mikrokügelchen
|
MX2007000891A
(es)
*
|
2004-07-23 |
2007-04-18 |
Genentech Inc |
Cristalizacion de anticuerpos o fragmentos de ellos.
|
US7772182B2
(en)
*
|
2004-08-05 |
2010-08-10 |
Alza Corporation |
Stable suspension formulations of erythropoietin receptor agonists
|
US20060029551A1
(en)
*
|
2004-08-05 |
2006-02-09 |
Kui Liu |
Stable particle formulations of erythropoietin receptor agonists
|
TW200621282A
(en)
*
|
2004-08-13 |
2006-07-01 |
Wyeth Corp |
Stabilizing formulations
|
US7572893B2
(en)
*
|
2004-08-17 |
2009-08-11 |
Regeneron Pharmaceuticals, Inc. |
IL-1 antagonist formulations
|
US7655758B2
(en)
|
2004-08-17 |
2010-02-02 |
Regeneron Pharmaceuticals, Inc. |
Stable liquid IL-1 antagonist formulations
|
US20060051347A1
(en)
*
|
2004-09-09 |
2006-03-09 |
Winter Charles M |
Process for concentration of antibodies and therapeutic products thereof
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
NZ560713A
(en)
|
2005-03-25 |
2010-11-26 |
Regeneron Pharma |
VEGF antagonist formulations
|
JP5620626B2
(ja)
|
2005-03-31 |
2014-11-05 |
中外製薬株式会社 |
会合制御によるポリペプチド製造方法
|
MX2007012896A
(es)
*
|
2005-04-15 |
2007-12-10 |
Schering Corp |
Metodos y composiciones para tratamiento o prevencion de cancer.
|
US7592429B2
(en)
|
2005-05-03 |
2009-09-22 |
Ucb Sa |
Sclerostin-binding antibody
|
WO2006125207A2
(en)
|
2005-05-19 |
2006-11-23 |
Amgen Inc. |
Compositions and methods for increasing the stability of antibodies
|
SG162788A1
(en)
|
2005-06-14 |
2010-07-29 |
Amgen Inc |
Self-buffering protein formulations
|
ES2627684T5
(es)
*
|
2005-11-01 |
2024-04-29 |
Wyeth Llc |
Solución de cloruro sódico para la reconstitución o la dilución de fármacos
|
US9309316B2
(en)
|
2005-12-20 |
2016-04-12 |
Bristol-Myers Squibb Company |
Stable subcutaneous protein formulations and uses thereof
|
WO2007076062A2
(en)
*
|
2005-12-21 |
2007-07-05 |
Wyeth |
Protein formulations with reduced viscosity and uses thereof
|
WO2007074880A1
(ja)
*
|
2005-12-28 |
2007-07-05 |
Chugai Seiyaku Kabushiki Kaisha |
抗体含有安定化製剤
|
AR059066A1
(es)
|
2006-01-27 |
2008-03-12 |
Amgen Inc |
Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
|
CA2638811A1
(en)
*
|
2006-02-03 |
2007-08-16 |
Medimmune, Llc |
Protein formulations
|
EP4342995A3
(de)
|
2006-03-31 |
2024-05-15 |
Chugai Seiyaku Kabushiki Kaisha |
Verfahren zur kontrolle der blut-pharmazeutizität von antikörpern
|
US9670269B2
(en)
|
2006-03-31 |
2017-06-06 |
Chugai Seiyaku Kabushiki Kaisha |
Methods of modifying antibodies for purification of bispecific antibodies
|
WO2007124082A2
(en)
*
|
2006-04-21 |
2007-11-01 |
Amgen, Inc. |
Buffering agents for biopharmaceutical formulations
|
KR101406811B1
(ko)
|
2006-06-16 |
2014-06-12 |
리제너론 파마슈티칼스 인코포레이티드 |
유리체내 투여에 적당한 vegf 길항제 제형
|
CN101500616A
(zh)
|
2006-08-04 |
2009-08-05 |
巴克斯特国际公司 |
预防和/或逆转新发作自身免疫糖尿病的基于微球的组合物
|
WO2008051363A2
(en)
|
2006-10-20 |
2008-05-02 |
Amgen Inc. |
Stable polypeptide formulations
|
CA2669424A1
(en)
|
2006-11-07 |
2008-05-29 |
Merck & Co., Inc. |
Antagonists of pcsk9
|
WO2008133647A2
(en)
*
|
2006-11-07 |
2008-11-06 |
Merck & Co., Inc. |
Antagonists of pcsk9
|
AU2008204901A1
(en)
*
|
2007-01-09 |
2008-07-17 |
Wyeth |
Anti-IL-13 antibody formulations and uses thereof
|
AU2008228823A1
(en)
*
|
2007-03-22 |
2008-09-25 |
Imclone Llc |
Stable antibody formulations
|
BRPI0809435A2
(pt)
|
2007-03-27 |
2014-09-09 |
Sea Lane Biotechnologies Llc |
Constructos e bibliotecas que compreendem sequências de cadeia leve substituida de anticorpos
|
AU2008233173B2
(en)
|
2007-03-29 |
2013-09-19 |
Abbvie Inc. |
Crystalline anti-human IL-12 antibodies
|
EP2703007A1
(de)
*
|
2007-03-30 |
2014-03-05 |
MedImmune, LLC |
Antikörper mit verminderten Deamidierungsprofilen
|
WO2008131129A2
(en)
*
|
2007-04-17 |
2008-10-30 |
Baxter International Inc. |
Nucleic acid microparticles for pulmonary delivery
|
EP2152233A1
(de)
|
2007-05-02 |
2010-02-17 |
Novo Nordisk Health Care AG |
Hochkonzentrierte faktor-vii-polypeptid-formulierungen mit einem aromatischen konservierungsmittel und einem antioxidans
|
EP2144624A1
(de)
*
|
2007-05-15 |
2010-01-20 |
Stryker Corporation |
Konzentrierte proteinpräparate aus knochenmorphogenetischen proteinen und verfahren zu ihrer verwendung
|
WO2008145351A1
(en)
|
2007-06-01 |
2008-12-04 |
F. Hoffmann-La Roche Ag |
Immunoglobulin purification
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
CL2008002775A1
(es)
|
2007-09-17 |
2008-11-07 |
Amgen Inc |
Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
|
DK2202245T3
(en)
|
2007-09-26 |
2016-11-21 |
Chugai Pharmaceutical Co Ltd |
A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
|
EP2219675B1
(de)
*
|
2007-11-12 |
2013-10-23 |
Ares Trading S.A. |
Formulierungen für taci-immunoglobulin-fusionsproteine
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
PE20091174A1
(es)
*
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
US11197916B2
(en)
|
2007-12-28 |
2021-12-14 |
Takeda Pharmaceutical Company Limited |
Lyophilized recombinant VWF formulations
|
JP5784907B2
(ja)
|
2007-12-28 |
2015-09-24 |
バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated |
組換え型vwf製剤
|
AR070315A1
(es)
*
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Anticuerpos 1b20 antagonistas de pcsk9
|
AR070316A1
(es)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
|
JP2011520999A
(ja)
*
|
2008-05-23 |
2011-07-21 |
ノボ ノルディスク ヘルス ケア アーゲー |
高濃度の芳香族保存料を有するペグ官能化セリンプロテアーゼの製剤
|
WO2009141433A1
(en)
*
|
2008-05-23 |
2009-11-26 |
Novo Nordisk Health Care Ag |
Low viscosity compositions comprising a pegylated gla-domain containing protein
|
EP2297203A1
(de)
*
|
2008-06-30 |
2011-03-23 |
Novo Nordisk A/S |
Anti-human-interleukin-20-antikörper
|
CN103919736A
(zh)
|
2008-10-21 |
2014-07-16 |
巴克斯特国际公司 |
冻干的重组vwf配方
|
JP2012510468A
(ja)
*
|
2008-11-28 |
2012-05-10 |
アボット・ラボラトリーズ |
安定な抗体組成物およびこれを安定させるための方法
|
SI2373681T1
(sl)
|
2008-12-10 |
2017-05-31 |
Glaxosmithkline Llc Corporation Service Company |
Farmacevtski sestavki albiglutida
|
US20130064834A1
(en)
|
2008-12-15 |
2013-03-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to pcsk9
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
EP2403873A1
(de)
|
2009-03-05 |
2012-01-11 |
Ablynx N.V. |
Neue antigenbindende dimerkomplexe, verfahren zur herstellung/vermeidung und anwendungen davon
|
US9265834B2
(en)
|
2009-03-05 |
2016-02-23 |
Ablynx N.V. |
Stable formulations of polypeptides and uses thereof
|
AU2010221156A1
(en)
*
|
2009-03-06 |
2011-09-22 |
Genentech, Inc. |
Antibody formulation
|
KR20120038406A
(ko)
*
|
2009-05-04 |
2012-04-23 |
애보트 바이오테크놀로지 리미티드 |
인간 항?TNF?α 항체의 안정한 고 단백질 농도 제형
|
US20120128671A1
(en)
|
2009-05-13 |
2012-05-24 |
Lawrence Horowitz |
Neutralizing molecules to influenza viruses
|
CA2767007C
(en)
|
2009-07-01 |
2017-11-21 |
Fresenius Medical Care Holdings, Inc. |
Drug delivery devices and related systems and methods
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
CN102573459A
(zh)
*
|
2009-08-04 |
2012-07-11 |
弗·哈夫曼-拉罗切有限公司 |
粘度降低的浓缩多肽制剂
|
US8221753B2
(en)
|
2009-09-30 |
2012-07-17 |
Tracon Pharmaceuticals, Inc. |
Endoglin antibodies
|
US8454956B2
(en)
*
|
2009-08-31 |
2013-06-04 |
National Cheng Kung University |
Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
|
EP2473527B1
(de)
|
2009-09-03 |
2016-11-30 |
Ablynx N.V. |
Stabile formulierungen von polypeptiden und verwendungen davon
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
EP2493922B1
(de)
|
2009-10-26 |
2017-02-15 |
F. Hoffmann-La Roche AG |
Verfahren zur herstellung von glycosyliertem immunoglobulin
|
BR112012009846B8
(pt)
*
|
2009-10-26 |
2021-05-25 |
Genentech Inc |
método in vitro e kit para detecção de um anticorpo antifármaco de isotipo ige, e uso de um anticorpo antifármaco de isotipo ige no tratamento de distúrbio mediado por ige
|
SI3409289T1
(sl)
|
2010-02-26 |
2020-12-31 |
Novo Nordisk A/S |
Stabilni sestavki, ki vsebujejo protitelo
|
USRE47150E1
(en)
|
2010-03-01 |
2018-12-04 |
Bayer Healthcare Llc |
Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
|
NZ602685A
(en)
|
2010-03-01 |
2014-10-31 |
Cytodyn Inc |
Concentrated protein formulations and uses thereof
|
US20110223208A1
(en)
*
|
2010-03-09 |
2011-09-15 |
Beth Hill |
Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
|
US9072668B2
(en)
|
2010-03-09 |
2015-07-07 |
Janssen Biotech, Inc. |
Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
|
EP2550018B1
(de)
|
2010-03-22 |
2019-02-27 |
F.Hoffmann-La Roche Ag |
Zusammensetzungen und verfahren zur stabilizierung von proteinen enthaltenden formulierungen
|
MX2012012743A
(es)
*
|
2010-05-03 |
2012-11-23 |
Genentech Inc |
Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina.
|
WO2011140176A1
(en)
|
2010-05-04 |
2011-11-10 |
Glaxosmithkline Llc |
Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
|
KR101861867B1
(ko)
*
|
2010-05-14 |
2018-05-29 |
암젠 인크 |
고농도의 항체 제제
|
BR112012030139A2
(pt)
|
2010-05-28 |
2017-06-13 |
Novo Nordisk As |
composições estáveis de anticorpos de doses múltiplas compreendendo um anticorpo e um preservante
|
WO2012003470A2
(en)
*
|
2010-07-02 |
2012-01-05 |
Medimmune, Llc |
Antibody formulations
|
KR20210021109A
(ko)
|
2010-11-08 |
2021-02-24 |
제넨테크, 인크. |
피하 투여용 항―il―6 수용체 항체
|
KR101841527B1
(ko)
|
2010-11-11 |
2018-03-23 |
애브비 바이오테크놀로지 리미티드 |
개선된 고농도 항-TNFα 항체 액체 제형
|
BR112013012213A2
(pt)
|
2010-11-17 |
2020-09-01 |
Chugai Seiyaku Kabushiki Kaisha |
moléculas de ligação a antígeno mul tlespecíficas tendo função alternativa à função dos fatores viii, ix e x de coagulação sanguínea, e anticorpo bies- 5 pecífico, seus usos na prevenção ou tratamento de hemorragia, ácido nucleico, vetor, célula, método para produzir as referidas moléculas de ligação, composição farmacêutica e kit
|
EP2668212B1
(de)
|
2011-01-28 |
2018-03-21 |
Sanofi Biotechnology |
Menschliche antikörper gegen psck9 zur verwendung in verfahren zur behandlung bestimmter gruppen von personen
|
MX356030B
(es)
|
2011-01-31 |
2018-05-09 |
Fresenius Medical Care Holdings Inc |
Prevencion de sobre-suministro de farmaco.
|
EP2673018B1
(de)
|
2011-02-08 |
2019-04-10 |
Fresenius Medical Care Holdings, Inc. |
Magnetische sensoren und zugehörige systeme und verfahren
|
CN103649118A
(zh)
|
2011-03-01 |
2014-03-19 |
安进公司 |
双特异性结合剂
|
CR20160147A
(es)
|
2011-03-25 |
2016-08-03 |
Amgen Inc |
Formulaciones de anticuerpos
|
EP2694708A4
(de)
*
|
2011-04-07 |
2014-10-01 |
Glaxosmithkline Llc |
Formulierungen mit reduzierter viskosität
|
EA201391488A1
(ru)
*
|
2011-04-07 |
2014-01-30 |
ГЛЭКСОСМИТКЛАЙН ЭлЭлСи |
Композиции со сниженной вязкостью
|
JO3283B1
(ar)
|
2011-04-26 |
2018-09-16 |
Sanofi Sa |
تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
|
AR087305A1
(es)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
CA2842860A1
(en)
|
2011-07-28 |
2013-01-31 |
Sea Lane Biotechnologies, Llc |
Sur-binding proteins
|
MX355816B
(es)
|
2011-08-04 |
2018-05-02 |
Amgen Inc |
Metodo para tratar los defectos de espacio oseo.
|
MY182178A
(en)
|
2011-09-01 |
2021-01-18 |
Chugai Pharmaceutical Co Ltd |
Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration
|
CN111789944A
(zh)
|
2011-09-16 |
2020-10-20 |
瑞泽恩制药公司 |
用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法
|
PE20141413A1
(es)
|
2011-10-25 |
2014-10-25 |
Onclave Therapeutics Ltd |
Formulaciones de anticuerpo y metodos
|
BR112014010186A2
(pt)
|
2011-10-28 |
2017-05-02 |
Integritybio Inc |
formulação farmacêutica estável, kit, composição farmacêutica, método para preparar uma formulação farmacêutica, e, método para tratar um humano ou animal
|
KR20140084078A
(ko)
|
2011-10-31 |
2014-07-04 |
제넨테크, 인크. |
항체 제제
|
CN104080468A
(zh)
|
2011-11-02 |
2014-10-01 |
哈尔西恩股份有限公司 |
用于创伤治疗的方法和组合物
|
WO2013070692A1
(en)
|
2011-11-07 |
2013-05-16 |
Battelle Memorial Institute |
Processes for delivery of viscous drug therapies
|
DK2596796T3
(da)
|
2011-11-24 |
2014-01-27 |
Quimera Ingenieria Biomedica S L |
Kompleks opnået af hyaluronsyre eller et salt deraf samt chondroitinsulfatblandinger
|
EP2793940B1
(de)
|
2011-12-22 |
2018-11-14 |
i2 Pharmaceuticals, Inc. |
Surrogatbindungsproteine
|
MX354270B
(es)
|
2011-12-28 |
2018-02-21 |
Amgen Inc |
Uso de un anticuerpo antiesclerostina en el tratamiento de la pérdida ósea alveolar. .
|
KR102063028B1
(ko)
|
2012-01-23 |
2020-01-07 |
리제너론 파아마슈티컬스, 인크. |
항-ang2 항체를 함유하는 안정화된 제형
|
US9144646B2
(en)
|
2012-04-25 |
2015-09-29 |
Fresenius Medical Care Holdings, Inc. |
Vial spiking devices and related assemblies and methods
|
KR102326359B1
(ko)
|
2012-05-18 |
2021-11-12 |
제넨테크, 인크. |
고농도 모노클로날 항체 제제
|
AR092325A1
(es)
|
2012-05-31 |
2015-04-15 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
|
US9617334B2
(en)
|
2012-06-06 |
2017-04-11 |
Zoetis Services Llc |
Caninized anti-NGF antibodies and methods thereof
|
BR112014031841A2
(pt)
*
|
2012-06-21 |
2017-06-27 |
Ucb Pharma Sa |
formulação farmacêutica
|
CN104619342A
(zh)
|
2012-07-05 |
2015-05-13 |
Ucb医药有限公司 |
骨疾病的治疗
|
US9221904B2
(en)
|
2012-07-19 |
2015-12-29 |
National Cheng Kung University |
Treatment of osteoarthritis using IL-20 antagonists
|
US8852588B2
(en)
|
2012-08-07 |
2014-10-07 |
National Cheng Kung University |
Treating allergic airway disorders using anti-IL-20 receptor antibodies
|
US8603470B1
(en)
|
2012-08-07 |
2013-12-10 |
National Cheng Kung University |
Use of IL-20 antagonists for treating liver diseases
|
FR2994390B1
(fr)
*
|
2012-08-10 |
2014-08-15 |
Adocia |
Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
|
US9592297B2
(en)
|
2012-08-31 |
2017-03-14 |
Bayer Healthcare Llc |
Antibody and protein formulations
|
US8613919B1
(en)
|
2012-08-31 |
2013-12-24 |
Bayer Healthcare, Llc |
High concentration antibody and protein formulations
|
UA115789C2
(uk)
|
2012-09-05 |
2017-12-26 |
Трейкон Фармасутікалз, Інк. |
Композиція антитіла до cd105 та її застосування
|
RS60226B1
(sr)
|
2012-09-07 |
2020-06-30 |
Coherus Biosciences Inc |
Stabilne vodene formulacije adalimumaba
|
FR2995214B1
(fr)
*
|
2012-09-10 |
2014-11-21 |
Adocia |
Solution a viscosite reduite de proteine a concentration elevee
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
KR101419884B1
(ko)
*
|
2012-11-27 |
2014-07-16 |
(주)알테오젠 |
단백질과 Fc 도메인을 융합한 융합 단백질의 안정화용 조성물
|
WO2014141149A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Formulations with reduced viscosity
|
LT2968434T
(lt)
|
2013-03-15 |
2017-09-25 |
Shire Viropharma Incorporated |
C1-inh kompozicijos, skirtos panaudoti paveldimos angiodemos prevencijai ir gydymui
|
US10111953B2
(en)
|
2013-05-30 |
2018-10-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
|
RU2674996C2
(ru)
|
2013-07-04 |
2018-12-14 |
Ф. Хоффманн-Ля Рош Аг |
Иммуноферментный анализ с подавлением интерференции для определения антител к лекарствам в образцах сыворотки
|
KR20180021234A
(ko)
|
2013-08-12 |
2018-02-28 |
제넨테크, 인크. |
보체-연관 상태의 치료를 위한 조성물 및 방법
|
WO2015038811A2
(en)
|
2013-09-11 |
2015-03-19 |
Arsia Therapeutics, Inc. |
Liquid protein formulations containing ionic liquids
|
JP6534615B2
(ja)
|
2013-09-27 |
2019-06-26 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
EP3882273A1
(de)
|
2013-11-12 |
2021-09-22 |
Sanofi Biotechnology |
Dosierschemata zur verwendung mit pcsk9-inhibitoren
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US9045545B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision medicine by targeting PD-L1 variants for treatment of cancer
|
US9034332B1
(en)
|
2014-07-15 |
2015-05-19 |
Kymab Limited |
Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
US8992927B1
(en)
|
2014-07-15 |
2015-03-31 |
Kymab Limited |
Targeting human NAV1.7 variants for treatment of pain
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US9023359B1
(en)
|
2014-07-15 |
2015-05-05 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
US8883157B1
(en)
|
2013-12-17 |
2014-11-11 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
US9067998B1
(en)
|
2014-07-15 |
2015-06-30 |
Kymab Limited |
Targeting PD-1 variants for treatment of cancer
|
US9045548B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
US9017678B1
(en)
|
2014-07-15 |
2015-04-28 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
US9051378B1
(en)
|
2014-07-15 |
2015-06-09 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
US9914769B2
(en)
|
2014-07-15 |
2018-03-13 |
Kymab Limited |
Precision medicine for cholesterol treatment
|
US8986694B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Targeting human nav1.7 variants for treatment of pain
|
US8945560B1
(en)
|
2014-07-15 |
2015-02-03 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
MA39934A
(fr)
|
2014-05-01 |
2017-03-08 |
Hoffmann La Roche |
Variants d'anticorps anti-facteur d et leurs utilisations
|
US10478498B2
(en)
|
2014-06-20 |
2019-11-19 |
Reform Biologics, Llc |
Excipient compounds for biopolymer formulations
|
WO2015196091A1
(en)
|
2014-06-20 |
2015-12-23 |
Reform Biologics, Llc |
Viscosity-reducing excipient compounds for protein formulations
|
US11357857B2
(en)
*
|
2014-06-20 |
2022-06-14 |
Comera Life Sciences, Inc. |
Excipient compounds for protein processing
|
US9139648B1
(en)
|
2014-07-15 |
2015-09-22 |
Kymab Limited |
Precision medicine by targeting human NAV1.9 variants for treatment of pain
|
US9150660B1
(en)
|
2014-07-15 |
2015-10-06 |
Kymab Limited |
Precision Medicine by targeting human NAV1.8 variants for treatment of pain
|
KR20230074283A
(ko)
|
2014-07-16 |
2023-05-26 |
사노피 바이오테크놀로지 |
이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
|
LT3170005T
(lt)
|
2014-07-18 |
2019-07-10 |
Sanofi |
Paciento, įtariamo, kad serga vėžiu, gydymo afliberceptu rezultato prognozavimo būdas
|
WO2016019969A1
(en)
|
2014-08-08 |
2016-02-11 |
Ludwig-Maximilians-Universität München |
Subcutaneously administered bispecific antibodies for use in the treatment of cancer
|
TWI700300B
(zh)
|
2014-09-26 |
2020-08-01 |
日商中外製藥股份有限公司 |
中和具有第viii凝血因子(fviii)機能替代活性的物質之抗體
|
TWI701435B
(zh)
|
2014-09-26 |
2020-08-11 |
日商中外製藥股份有限公司 |
測定fviii的反應性之方法
|
JP6716577B2
(ja)
|
2014-10-01 |
2020-07-01 |
イーグル・バイオロジクス・インコーポレイテッドEagle Biologics, Inc. |
粘度低下物質を含有する、多糖および核酸の調合薬
|
TW201628649A
(zh)
|
2014-10-09 |
2016-08-16 |
再生元醫藥公司 |
減少醫藥調配物中微可見顆粒之方法
|
WO2016059512A1
(en)
*
|
2014-10-18 |
2016-04-21 |
Pfizer Inc. |
Anti-il-7r antibody compositions
|
ES2749383T3
(es)
|
2014-11-06 |
2020-03-20 |
Hoffmann La Roche |
Variantes de la región Fc con unión al FcRn modificada y procedimientos de uso
|
CA2966905A1
(en)
|
2014-11-12 |
2016-05-19 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
US9926375B2
(en)
|
2014-11-12 |
2018-03-27 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
MA41142A
(fr)
|
2014-12-12 |
2017-10-17 |
Amgen Inc |
Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
|
CN107206080B
(zh)
|
2015-01-28 |
2022-07-08 |
辉瑞公司 |
稳定的水性抗血管内皮细胞生长因子(vegf)抗体制剂
|
AR103726A1
(es)
|
2015-02-27 |
2017-05-31 |
Merck Sharp & Dohme |
Cristales de anticuerpos monoclonales anti-pd-1 humanos
|
JP7082484B2
(ja)
|
2015-04-01 |
2022-06-08 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
US11173197B2
(en)
*
|
2015-07-07 |
2021-11-16 |
Bluewillow Biologics, Inc. |
Methods and compositions for nanoemulsion vaccine formulations
|
WO2017007837A1
(en)
*
|
2015-07-07 |
2017-01-12 |
Nanobio Corporation |
Methods and compositions for the stabilizaton of proteins
|
US20170007690A1
(en)
*
|
2015-07-07 |
2017-01-12 |
Nanobio Corporation |
Methods and compositions for the stabilization of anthrax recombinant protective antigen
|
EP4209499A1
(de)
|
2015-08-13 |
2023-07-12 |
Amgen Inc. |
Geladene tiefenfiltration von antigenbindenden proteinen
|
JP2018523684A
(ja)
|
2015-08-18 |
2018-08-23 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗pcsk9阻害抗体
|
US11229702B1
(en)
|
2015-10-28 |
2022-01-25 |
Coherus Biosciences, Inc. |
High concentration formulations of adalimumab
|
TW201730211A
(zh)
|
2015-10-30 |
2017-09-01 |
建南德克公司 |
抗因子d抗體及結合物
|
CN108472382A
(zh)
|
2015-10-30 |
2018-08-31 |
豪夫迈·罗氏有限公司 |
抗-因子d抗体变体缀合物及其用途
|
CN108368166B
(zh)
|
2015-12-28 |
2023-03-28 |
中外制药株式会社 |
提高含fc区多肽纯化效率的方法
|
GB201604124D0
(en)
|
2016-03-10 |
2016-04-27 |
Ucb Biopharma Sprl |
Pharmaceutical formulation
|
US11071782B2
(en)
|
2016-04-20 |
2021-07-27 |
Coherus Biosciences, Inc. |
Method of filling a container with no headspace
|
MA44780A
(fr)
|
2016-04-28 |
2019-03-06 |
Chugai Pharmaceutical Co Ltd |
Préparation contenant un anticorps
|
EP3254671B1
(de)
|
2016-06-10 |
2019-11-13 |
Octapharma AG |
Hochkonzentrierte immunglobulinzusammensetzung zur pharmazeutischen anwendung
|
WO2018024873A1
(en)
|
2016-08-05 |
2018-02-08 |
Csl Behring Gmbh |
Pharmaceutical formulations of c1 esterase inhibitor
|
CA3031742A1
(en)
|
2016-08-16 |
2018-02-22 |
Regeneron Pharmaceuticals, Inc. |
Methods for quantitating individual antibodies from a mixture
|
CN109661241A
(zh)
|
2016-09-06 |
2019-04-19 |
中外制药株式会社 |
使用识别凝血因子ix和/或活化凝血因子ix以及凝血因子x和/或活化凝血因子x的双特异性抗体的方法
|
JP6884858B2
(ja)
|
2016-10-21 |
2021-06-09 |
アムジエン・インコーポレーテツド |
医薬製剤及びその製造方法
|
DK3532838T3
(da)
|
2016-10-25 |
2022-07-04 |
Regeneron Pharma |
Fremgangsmåder og systemer til kromatografidataanalyse
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
EP3618871A4
(de)
|
2017-05-02 |
2021-01-06 |
Merck Sharp & Dohme Corp. |
Formulierungen von anti-lag3-antikörpern und co-formulierungen von anti-lag3-antikörpern und anti-pd-1-antikörpern
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
EP3624846A1
(de)
|
2017-05-16 |
2020-03-25 |
Bhami's Research Laboratory, Pvt. Ltd. |
Hochkonzentrierte proteinformulierungen mit reduzierter viskosität
|
US11655289B2
(en)
|
2017-08-22 |
2023-05-23 |
Biogen Ma Inc. |
Pharmaceutical compositions containing anti-beta amyloid antibodies
|
US10759870B2
(en)
|
2017-09-29 |
2020-09-01 |
Chugai Seiyaku Kabushiki Kaisha |
Multispecific antigen-binding molecules having blood coagulation factor VIII (FVIII) cofactor function-substituting activity and pharmaceutical formulations containing such a molecule as an active ingredient
|
CA3093457A1
(en)
|
2018-03-30 |
2019-10-03 |
Amgen Inc. |
C-terminal antibody variants
|
CN111989121A
(zh)
|
2018-04-16 |
2020-11-24 |
默克专利股份有限公司 |
高浓缩蛋白质制剂的粘度降低
|
JOP20200275A1
(ar)
|
2018-05-10 |
2020-11-02 |
Regeneron Pharma |
صيغ تحتوي على بروتين اندماج لمستقبلvegf مرتفعة التركيز
|
TW202016125A
(zh)
*
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
TW202005694A
(zh)
|
2018-07-02 |
2020-02-01 |
美商里珍納龍藥品有限公司 |
自混合物製備多肽之系統及方法
|
TW202011995A
(zh)
*
|
2018-07-03 |
2020-04-01 |
比利時商葛萊伯格有限公司 |
高濃度液體抗體配製物
|
IL267923B2
(en)
*
|
2018-08-02 |
2023-06-01 |
Grifols Worldwide Operations Ltd |
The composition containing the most concentrated alpha-1 type protein inhibitor and a method for obtaining it
|
CA3152838A1
(en)
*
|
2019-08-30 |
2021-03-04 |
Kashiv Biosciences, Llc |
Novel formulation of highly concentrated pharmacologically active antibody
|
EP3808777A1
(de)
|
2019-10-16 |
2021-04-21 |
Glenmark Specialty S.A. |
Stabile flüssige antikörperformulierungen
|
AU2021308997A1
(en)
|
2020-07-13 |
2023-02-02 |
Merck Patent Gmbh |
Viscosity reducing excipients and combinations thereof for highly concentrated protein formulations
|
AR123085A1
(es)
|
2020-07-31 |
2022-10-26 |
Genentech Inc |
FORMULACIONES DE ANTICUERPO ANTI-INTEGRINA b7 Y DISPOSITIVOS
|
WO2023175035A1
(en)
*
|
2022-03-15 |
2023-09-21 |
Adrenomed Ag |
Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment
|